# CJC-1295 References and Citations

> Full citation list for the CJC-1295 research dossier — peer-reviewed studies, FDA briefing materials, and WADA documentation underlying every quantitative claim on the site.

_Every quantitative claim in the dossier maps to a numbered citation here — Phase I trial, foundational receptor pharmacology, regulatory briefings, and the broader GHRH-analog class literature._

## Reference table

The CJC-1295 references and citations on this page constitute the full source set for the dossier. Nineteen entries: the foundational Phase I human dose-escalation trial (Teichman 2006), the GHRH-receptor mechanism papers (Jetté 2005, Alba 2006, Frohman 1995, Zhou 2020, the 2025 GHRHR review), the ipamorelin and GH-secretagogue characterization (Raun 1998, Ishida 2020), the tesamorelin class comparator (Falutz 2007, Stanley 2014), the modified GRF (1-29) chemistry reference, the ConjuChem Phase II halt reporting, the FDA Pharmacy Compounding Advisory Committee briefing, the FDA 503A bulks-list action coverage, the WADA Prohibited List 2026, the long-term GH-treatment safety analysis (Johannsson 2022), and the historical sermorelin pharmacology reference (Frohman 1995). DOIs and PubMed identifiers are listed where available; URLs link to the canonical archive.

All citations are organized by section below in canonical order — peer-reviewed primary research, peer-reviewed reviews, regulatory documentation, and historical / class-context references. Citations marked with PMID or DOI are direct links to the public PubMed or publisher archive.

## References

[1] Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536 PMID:16352683 https://pubmed.ncbi.nlm.nih.gov/16352683/

[2] Teichman SL, et al. CJC-1295 Phase I pharmacokinetics — half-life and IGF-1 elevation duration data. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536 PMID:16352683 https://pubmed.ncbi.nlm.nih.gov/16352683/

[3] Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286 PMID:15817669 https://pubmed.ncbi.nlm.nih.gov/15817669/

[4] Jetté L, et al. CJC-1295 albumin-conjugation pharmacokinetics in rats — peptide detectable in plasma beyond 72 hours, 4-fold GH AUC over unmodified GRF. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286 PMID:15817669 https://pubmed.ncbi.nlm.nih.gov/15817669/

[5] Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00201.2006 PMID:16822960 https://pubmed.ncbi.nlm.nih.gov/16822960/

[6] Teichman SL, et al. Safety and tolerability of CJC-1295 in Phase I dose escalation — no serious adverse reactions; injection-site reactions and transient flushing reported. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536 PMID:16352683 https://pubmed.ncbi.nlm.nih.gov/16352683/

[7] Growth hormone-releasing hormone receptor (GHRH-R) and its signaling (review). Rev Endocr Metab Disord. 2025. doi:10.1007/s11154-025-09952-x PMID:PMC12137518 https://pmc.ncbi.nlm.nih.gov/articles/PMC12137518/

[8] Zhou F, Zhang H, Cong Z, Zhao LH, et al. Structural basis for activation of the growth hormone-releasing hormone receptor. Nat Commun. 2020;11(1):5205. doi:10.1038/s41467-020-18945-0 https://www.nature.com/articles/s41467-020-18945-0

[9] Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. doi:10.1530/eje.0.1390552 PMID:9849822 https://academic.oup.com/ejendo/article-abstract/139/5/552/6748390

[10] Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications. 2020;3(1):25-37. doi:10.1002/rco2.9 https://onlinelibrary.wiley.com/doi/full/10.1002/rco2.9

[11] Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. doi:10.1056/NEJMoa072375 PMID:18046029 https://www.nejm.org/doi/full/10.1056/NEJMoa072375

[12] Modified GRF (1-29) — chemistry and pharmacology overview (review compendium, citing primary GRF analog literature). https://en.wikipedia.org/wiki/Modified_GRF_(1-29)

[13] Aidsmap editorial. Lipodystrophy study halted after patient death (news report on ConjuChem Phase II CJC-1295 trial). aidsmap.com. 2006. https://www.aidsmap.com/news/jul-2006/lipodystrophy-study-halted-after-patient-death

[14] U.S. Food and Drug Administration. FDA Briefing Document — Pharmacy Compounding Advisory Committee (PCAC) Meeting on peptide bulk drug substances. 2024. https://www.fda.gov/media/183819/download

[15] World Anti-Doping Agency. The Prohibited List — International Standard (Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics). WADA Prohibited List 2026. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf

[16] Johannsson G, Touraine P, Feldt-Rasmussen U, et al. Long-term safety of growth hormone in adults with growth hormone deficiency: overview of 15,809 GH-treated patients. J Clin Endocrinol Metab. 2022. doi:10.1210/clinem/dgac199 PMID:PMC9202689 https://pmc.ncbi.nlm.nih.gov/articles/PMC9202689/

[17] Lexology editorial. FDA removes certain peptide bulk drug substances from Category 2 of interim 503A bulks list and sets dates for PCAC review. 2024. https://www.lexology.com/library/detail.aspx?g=2e55b76a-3173-4e04-beda-bf021202f18d

[18] Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. doi:10.1001/jama.2014.8334 https://jamanetwork.com/journals/jama/fullarticle/1889139

[19] Frohman LA, Kineman RD. Growth hormone-releasing hormone: synthesis and signaling. Recent Prog Horm Res. 1995;50:65-110. PMID:7740167 https://pubmed.ncbi.nlm.nih.gov/7740167/

---

A compounding-pharmacy reading room for the CJC-1295 research record — Phase I evidence rendered in solid rules, gray-literature claims in dashed ones, no scripts filled on the premises.